Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study in Subjects With Moderate Atopic Dermatitis

ClinicalTrials.gov ID: NCT03175354

Public ClinicalTrials.gov record NCT03175354. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of the Safety and Efficacy of ALX-101 Topical Gel Administered Twice Daily in Adult and Adolescent Subjects With Moderate Atopic Dermatitis

Study identification

NCT ID
NCT03175354
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Ralexar Therapeutics, Inc.
Industry
Enrollment
209 participants

Conditions and interventions

Interventions

  • ALX-101 Gel 1.5% and ALX-101 Gel Vehicle Drug
  • ALX-101 Gel 5% and ALX-101 Gel Vehicle Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 25, 2017
Primary completion
Jun 28, 2018
Completion
Jun 28, 2018
Last update posted
Oct 24, 2018

2017 – 2018

United States locations

U.S. sites
35
U.S. states
20
U.S. cities
31
Facility City State ZIP Site status
Ralexar Investigational Site 35 Anniston Alabama 36207
Ralexar Investigational Site 21 Birmingham Alabama 35209
Ralexar Investigational Site 18 Laguna Hills California 92653
Ralexar Investigational Site 23 Los Angeles California 90045
Ralexar Investigational Site 24 Oceanside California 92056
Ralexar Investigational Site 34 San Diego California 92103
Ralexar Investigational Site 16 San Diego California 92108
Ralexar Investigational Site 33 San Diego California 92121
Ralexar Investigational Site 27 Santa Monica California 90404
Ralexar Investigational Site 1 Miami Florida 33143
Ralexar Investigational Site 14 Pinellas Park Florida 33781
Ralexar Investigational Site 22 Tampa Florida 33618
Ralexar Investigational Site 29 Snellville Georgia 30078
Ralexar Investigational Site 17 New Albany Indiana 47150
Ralexar Investigational Site 32 Louisville Kentucky 40202
Ralexar Investigational Site 7 Louisville Kentucky 40241
Ralexar Investigational Site 11 Warren Michigan 48088
Ralexar Investigational Site 15 Fridley Minnesota 55432
Ralexar Investigational Site 25 Saint Joseph Missouri 64506
Ralexar Investigational Site 26 Albuquerque New Mexico 87106
Ralexar Investigational Site 20 New York New York 10075
Ralexar Investigational Site 30 Stony Brook New York 11790
Ralexar Investigational Site 28 Charlotte North Carolina 28217
Ralexar Investigational Site 12 Beachwood Ohio 44122
Ralexar Investigational Site 5 Cincinnati Ohio 45236
Ralexar Investigational Site 3 Oklahoma City Oklahoma 73112
Ralexar Investigational Site 8 Johnston Rhode Island 02919
Ralexar Investigational Site 6 Spartanburg South Carolina 29303
Ralexar Investigational Site 9 Nashville Tennessee 37215
Ralexar Investigational Site 19 Austin Texas 78745
Ralexar Investigational Site 31 Austin Texas 78759
Ralexar Investigational Site 4 Plano Texas 75024
Ralexar Investigational Site 2 San Antonio Texas 78218
Ralexar Investigational Site 13 Richmond Virginia 23220
Ralexar Investigational Site 10 Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03175354, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 24, 2018 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03175354 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →